- Active ingredient
- tigecycline
- Strength
- 50 mg
- Form
- vial
- Manufacturer
- pfizer
- Route
- injection
Uses
Tigecycline is a tetracycline-class antibacterial indicated for adults with complicated skin and skin structure infections, complicated intra-abdominal infections, and community-acquired bacterial pneumonia caused by susceptible organisms.
Do not use if
Contraindicated in patients with known hypersensitivity to tigecycline or any excipient. Anaphylactic reactions have been reported.
Side effects
The most common adverse effects are nausea, vomiting, and diarrhea. Serious risks include increased all-cause mortality compared to comparators, hepatic dysfunction, pancreatitis, and anaphylactic reactions.
Warnings
Boxed warning: increased all-cause mortality observed in clinical trials; use only when alternatives are unsuitable. Not indicated for hospital-acquired or ventilator-associated pneumonia or diabetic foot infections. Monitor for hepatic adverse effects.
How it works
Tigecycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, blocking entry of amino-acyl tRNA. It overcomes major tetracycline resistance mechanisms including efflux pumps and ribosomal protection.
Storage
Store unreconstituted powder at controlled room temperature. Once reconstituted and diluted, use within the time specified in the prescribing information.
